FDA Breakthrough Therapy Designation Signals Accelerated Path

May 29, 2026 - Merck (NYSE: MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to calderasib (MK-1084), an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA (pembrolizumab) for first-line treatment of advanced or metastatic NSCLC with KRAS G12C mutation and PD-L1 expression (TPS 1% or higher).

This is the first Breakthrough Therapy designation for calderasib, supported by positive data from the Phase 1 KANDLELIT-001 trial. The designation provides Merck with intensive FDA guidance, rolling review, and potential Priority Review eligibility.

KRAS G12C: From Undruggable to Therapeutic Target

The KRAS G12C mutation occurs in approximately 14% of NSCLC adenocarcinoma cases. For decades, KRAS was considered undruggable. Calderasib is a highly potent next-generation KRAS G12C covalent inhibitor, developed through collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals (Otsuka subsidiary).

From the Phase 1 KANDLELIT-001 trial, calderasib monotherapy (n=21) achieved a 38% objective response rate in KRAS G12C-mutant NSCLC. The combination with pembrolizumab is expected to enhance efficacy through complementary mechanisms.

The KANDLELIT Clinical Program: Five Phase 3 Trials

• KANDLELIT-004: Calderasib + KEYTRUDA in newly diagnosed metastatic NSCLC with KRAS G12C mutation and PD-L1 TPS 50% or higher
• KANDLELIT-007: Calderasib + KEYTRUDA QLEX in newly diagnosed advanced NSCLC with KRAS G12C mutation, regardless of PD-L1
• KANDLELIT-012: Calderasib + cetuximab + mFOLFOX6 in first-line KRAS G12C-mutated colorectal cancer
• KANDLELIT-013: Calderasib + KEYTRUDA QLEX in locally advanced KRAS G12C-mutated NSCLC after neoadjuvant/adjuvant therapy
• KANDLELIT-015: Calderasib + durvalumab in locally advanced KRAS G12C-mutated NSCLC after chemoradiation

The breadth of this program underscores the large addressable patient population and calderasib potential to become a cornerstone of KRAS G12C-directed therapy across multiple tumor types.

API and Intermediate Manufacturing Implications

Calderasib is an oral small molecule covalent KRAS G12C inhibitor, creating distinct manufacturing opportunities:

• Complex small molecule synthesis: The covalent warhead and targeted binding moiety require multi-step synthetic sequences with high selectivity
• Advanced intermediates: The synthesis route involves chiral building blocks and specialized reagents for covalent bond-forming steps
• Process chemistry services: Route optimization and scale-up support as the compound moves through Phase 3
• GMP API production: Commercial-scale manufacturing will require dedicated capacity with validated analytical methods
• Impurity profiling: Regulatory agencies will require comprehensive impurity characterization for covalent inhibitors

For CDMOs and intermediate suppliers, the five Phase 3 trials represent sustained demand for clinical-stage API supply, with commercial volumes expected to multiply upon approval.

Market Opportunity: The KRAS Inhibitor Landscape

The KRAS G12C inhibitor market is rapidly expanding. Sotorasib (Lumakras, Amgen) and adagrasib (Krazati, Mirati/BMS) were the first two approved, but both face limitations. Calderasib combination with pembrolizumab represents a differentiated approach that could redefine the treatment paradigm.

NSCLC affects approximately 230,000 Americans annually. With KRAS G12C mutations in roughly 14% of adenocarcinomas, the addressable population exceeds 30,000 patients per year in the US alone. For API suppliers, calderasib Breakthrough Therapy designation signals high probability of commercial success and substantial long-term demand.